The MET oncogene is amplified in a fraction of human gastric carcinoma cell lines, with consequent overexpression and constitutive activation of the corresponding protein product, the Met tyrosine kinase receptor. This genetically driven hyperactivation of Met is necessary for cancer cell growth and survival, so that Met pharmacological blockade results in cell-cycle arrest or apoptosis (oncogene addiction). MET gene amplification also occurs in vivo in a number of human gastric carcinomas, and clinical trials are now ongoing to assess the therapeutic efficacy of Met inhibitors in this type of malignancy. The aim of our study was to identify a preclinical algorithm of soluble surrogate biomarkers indicative of response to Met inhibition in gastric tumors, as a potential tool to integrate imaging criteria during patient follow-up. We started from a survey of candidate molecules based on antibody proteomics and gene expression profiling; after ELISA validation and analytical quantification, four biomarkers were identified that appeared to be strongly and consistently modulated by Met inhibition in a panel of Met-addicted gastric carcinoma cell lines, but not in Met-independent cell lines. Pharmacologic blockade of Met using specific small-molecule inhibitors led to reduced secretion of IL-8, GROα and the soluble form of uPAR and to increased production of IL-6 both in vitro (in culture supernatants) and in vivo (in the plasma of xenografted mice). If confirmed in patients, this information might prove useful to monitor clinical response to Met-targeted therapies in MET-amplified gastric carcinomas.

A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.

TORTI, DAVIDE;SASSI, FRANCESCO;GALIMI, Francesco;GASTALDI, Stefania;COMOGLIO, Paolo;TRUSOLINO, Livio;BERTOTTI, Andrea
2012

Abstract

The MET oncogene is amplified in a fraction of human gastric carcinoma cell lines, with consequent overexpression and constitutive activation of the corresponding protein product, the Met tyrosine kinase receptor. This genetically driven hyperactivation of Met is necessary for cancer cell growth and survival, so that Met pharmacological blockade results in cell-cycle arrest or apoptosis (oncogene addiction). MET gene amplification also occurs in vivo in a number of human gastric carcinomas, and clinical trials are now ongoing to assess the therapeutic efficacy of Met inhibitors in this type of malignancy. The aim of our study was to identify a preclinical algorithm of soluble surrogate biomarkers indicative of response to Met inhibition in gastric tumors, as a potential tool to integrate imaging criteria during patient follow-up. We started from a survey of candidate molecules based on antibody proteomics and gene expression profiling; after ELISA validation and analytical quantification, four biomarkers were identified that appeared to be strongly and consistently modulated by Met inhibition in a panel of Met-addicted gastric carcinoma cell lines, but not in Met-independent cell lines. Pharmacologic blockade of Met using specific small-molecule inhibitors led to reduced secretion of IL-8, GROα and the soluble form of uPAR and to increased production of IL-6 both in vitro (in culture supernatants) and in vivo (in the plasma of xenografted mice). If confirmed in patients, this information might prove useful to monitor clinical response to Met-targeted therapies in MET-amplified gastric carcinomas.
130
6
1357
1366
http://dx.doi.org/10.1002/ijc.26137
Animals, Cell Line; Tumor, Chemokine CXCL1; blood/genetics/metabolism, Female, Gene Expression Profiling, Humans, Indoles; pharmacology, Interleukin-6; blood/genetics/metabolism, Interleukin-8; blood/genetics/metabolism, Mannose-Binding Lectins; blood/genetics/metabolism, Membrane Glycoproteins; blood/genetics/metabolism, Mice, Mice; Nude, Proteomics, Proto-Oncogene Proteins c-met; antagonists /&/ inhibitors/genetics/metabolism, Receptors; Cell Surface; blood/genetics/metabolism, Stomach Neoplasms; blood/drug therapy/genetics/metabolism, Sulfones; pharmacology, Tumor Markers; Biological; blood/genetics/metabolism, Xenograft Model Antitumor Assays
D. Torti;F. Sassi;F. Galimi;S. Gastaldi;T. Perera;P. M. Comoglio;L. Trusolino*; A. Bertotti* (*Co-Senior Authors)
File in questo prodotto:
File Dimensione Formato  
2012_A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 672.86 kB
Formato Adobe PDF
672.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
torti et al 2012.pdf

Accesso aperto con embargo fino al 15/03/2013

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 783.91 kB
Formato Adobe PDF
783.91 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/102468
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 16
social impact